Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 682717, 9 pages
http://dx.doi.org/10.1155/2014/682717
Review Article

Comparison of Two Old Phytochemicals versus Two Newly Researched Plant-Derived Compounds: Potential for Brain and Other Relevant Ailments

1Brain Research Center, Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong
2Brain Research Center, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong

Received 11 December 2013; Revised 31 March 2014; Accepted 15 April 2014; Published 8 May 2014

Academic Editor: Andrew Newberg

Copyright © 2014 Chun-Mei Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Shi, Z. Yao, J. Xu, and D. T. Yew, “Effects of Gingko Extract (EGb761) on oxidative damage under different conditions of serum supply,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 1, pp. 61–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Shi, L. Zhao, B. Zhu et al., “Dosage effects of EGb761 on hydrogen peroxide-induced cell death in SH-SY5Y cells,” Chemico-Biological Interactions, vol. 180, no. 3, pp. 389–397, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Shi, S. Xiao, J. Liu et al., “Ginkgo biloba extract EGb761 protects against aging-associated mitochondrial dysfunction in platelets and hippocampi of SAMP8 mice,” Platelets, vol. 21, no. 5, pp. 373–379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Shi, L. Fang, D. T. Yew, Z. Yao, and J. Xu, “Ginkgo biloba extract EGb761 protects against mitochondrial dysfunction in platelets and hippocampi in ovariectomized rats,” Platelets, vol. 21, no. 1, pp. 53–59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Chandrasekaran, Z. Mehrabian, B. Spinnewyn, C. Chinopoulos, K. Drieu, and G. Fiskum, “Neuroprotective effects of bilobalide, a component of Ginkgo biloba extract (EGb 761) in global brain ischemia and in excitotoxicity-induced neuronal death,” Pharmacopsychiatry, vol. 36, no. 1, pp. S89–S94, 2003. View at Google Scholar · View at Scopus
  6. B. Ahlemeyer and J. Krieglstein, “Neuroprotective effects of Ginkgo biloba extract,” Cellular and Molecular Life Sciences, vol. 60, no. 9, pp. 1779–1792, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Shi, F. Wu, D. T. Yew, J. Xu, and Y. Zhu, “Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells,” Apoptosis, vol. 15, no. 6, pp. 715–727, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Shi, L. Zhao, B. Zhu et al., “Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against β-amyloid peptide-induced toxicity in SH-SY5Y cells,” Chemico-Biological Interactions, vol. 181, no. 1, pp. 115–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. F. V. DeFeudis and K. Drieu, “Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications,” Current Drug Targets, vol. 1, no. 1, pp. 25–58, 2000. View at Google Scholar · View at Scopus
  10. B. Ahlemeyer and J. Krieglstein, “Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease,” Pharmacopsychiatry, vol. 36, no. 1, pp. S8–S14, 2003. View at Google Scholar · View at Scopus
  11. D. Loew, “Value of Ginkgo biloba in treatment of Alzheimer dementia,” Wiener Medizinische Wochenschrift, vol. 152, no. 15-16, pp. 418–422, 2002. View at Google Scholar · View at Scopus
  12. M. Mazza, A. Capuano, P. Bria, and S. Mazza, “Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study,” European Journal of Neurology, vol. 13, no. 9, pp. 981–985, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Schulz, “Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider,” Phytomedicine, vol. 10, no. 4, pp. 74–79, 2003. View at Google Scholar · View at Scopus
  14. A. Wettstein, “Cholinesterase inhibitors and Gingko extracts–are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration,” Phytomedicine, vol. 6, no. 6, pp. 393–401, 2000. View at Google Scholar · View at Scopus
  15. S. Kanowski and R. Hoerr, “Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial,” Pharmacopsychiatry, vol. 36, no. 6, pp. 297–303, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. P. L. Le Bars, F. M. Velasco, J. M. Ferguson, E. C. Dessain, M. Kieser, and R. Hoerr, “Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease,” Neuropsychobiology, vol. 45, no. 1, pp. 19–26, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Shi, J. Liu, F. Wu, and D. T. Yew, “Ginkgo biloba extract in Alzheimer's disease: from action mechanisms to medical practice,” International Journal of Molecular Sciences, vol. 11, no. 1, pp. 107–123, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. D. T. Yew, H. W. Wong, W. P. Li, H. W. L. Lai, and W.-H. A. Yu, “Nitric oxide synthase neurons in different areas of normal aged and Alzheimer's brains,” Neuroscience, vol. 89, no. 3, pp. 675–686, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Bastianetto, W.-H. Zheng, and R. Quirion, “The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C,” Journal of Neurochemistry, vol. 74, no. 6, pp. 2268–2277, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Liu, Y. Hu, D.-H. Guo et al., “Potential antidepressant properties of Radix Polygalae (Yuan Zhi),” Phytomedicine, vol. 17, no. 10, pp. 794–799, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Lin, J. Gu, J. Xiu, T. Mi, J. Dong, and J. K. Tiwari, “Traditional Chinese medicine for senile dementia,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 692621, 13 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Ikeya, S. Takeda, M. Tunakawa et al., “Cognitive improving and cerebral protective effects of acylated oligosaccharides in Polygala tenuifolia,” Biological and Pharmaceutical Bulletin, vol. 27, no. 7, pp. 1081–1085, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. C. I. Lee, J. Y. Han, J. T. Hong, and K. W. Oh, “3, 4, 5-trimethoxycinnamic acid (TMCA), one of the constituents of Polygalae Radix enhances pentobarbital-induced sleeping behaviors via GABAAergic systems in mice,” Archives of Pharmacal Research, vol. 36, no. 10, pp. 1244–1251, 2013. View at Publisher · View at Google Scholar
  24. Y. Hu, J. Li, P. Liu et al., “Protection of SH-SY5Y neuronal cells from glutamate-induced apoptosis by 3,6 ′-disinapoyl sucrose, a bioactive compound isolated from radix polygala,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 728342, 5 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Li, J. Yang, S. Yu et al., “Triterpenoid saponins with neuroprotective effects from the roots of Polygala tenuifolia,” Planta Medica, vol. 74, no. 2, pp. 133–141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Kawashima, D. Miyako, Y. Ishino, T. Makino, K.-I. Saito, and Y. Kano, “Anti-stress effects of 3,4,5-trimethoxycinnamic acid, an active constituent of roots of Polygala tenuifolia (Onji),” Biological and Pharmaceutical Bulletin, vol. 27, no. 8, pp. 1317–1319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Y. Zhu, Q. Q. Mao, S. P. Ip et al., “A standardized chinese herbal decoction, kai-xin-san, restores decreased levels of neurotransmitters and neurotrophic factors in the brain of chronic stress-induced depressive rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 149256, 13 pages, 2012. View at Publisher · View at Google Scholar
  28. J. G. Choi, H. G. Kim, M. C. Kim et al., “Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models,” Journal of Ethnopharmacology, vol. 134, no. 2, pp. 414–421, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. H.-J. Park, K. Lee, H. Heo et al., “Effects of Polygala tenuifolia root extract on proliferation of neural stem cells in the hippocampal CA1 region,” Phytotherapy Research, vol. 22, no. 10, pp. 1324–1329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Zhang, T. Han, L. Zhang et al., “Effects of tenuifolin extracted from radix polygalae on learning and memory: a behavioral and biochemical study on aged and amnesic mice,” Phytomedicine, vol. 15, no. 8, pp. 587–594, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. X.-L. Sun, H. Ito, T. Masuoka, C. Kamei, and T. Hatano, “Effect of Polygala tenuifolia root extract on scopolamine-induced impairment of rat spatial cognition in an eight-arm radial maze task,” Biological and Pharmaceutical Bulletin, vol. 30, no. 9, pp. 1727–1731, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Y. Shin, J.-Y. Lee, B. Y. Won et al., “BT-11 is effective for enhancing cognitive functions in the elderly humans,” Neuroscience Letters, vol. 465, no. 2, pp. 157–159, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Yabe, S. Iizuka, Y. Komatsu, and H. Yamada, “Enhancements of choline acetyltransferase activity and nerve growth factor secretion by Polygalae radix-extract containing active ingredients in Kami-untan-to,” Phytomedicine, vol. 4, no. 3, pp. 199–205, 1997. View at Google Scholar · View at Scopus
  34. J. Li, K.-W. Zeng, S.-P. Shi, Y. Jiang, and P.-F. Tu, “Anti-neuroinflammatory constituents from Polygala tricornis Gagnep,” Fitoterapia, vol. 83, no. 5, pp. 896–900, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. J.-H. Park, J. S. Kim, D. S. Jang, and S.-M. Lee, “Effect of Polygala tenuifolia root extract on cerebral ischemia and reperfusion,” American Journal of Chinese Medicine, vol. 34, no. 1, pp. 115–123, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M.-C. Cheng, C.-Y. Li, H.-C. Ko, F.-N. Ko, Y.-L. Lin, and T.-S. Wu, “Antidepressant principles of the roots of Polygala tenuifolia,” Journal of Natural Products, vol. 69, no. 9, pp. 1305–1309, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. A. S. Limpert, M. E. Mattmann, and N. D. Cosford, “Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS),” Beilstein Journal of Organic Chemistry, vol. 9, pp. 717–732, 2013. View at Publisher · View at Google Scholar
  38. L. Zhang, W. H. Yu, Y. X. Wang et al., “DL-3-n-Butylphthalide, an anti-oxidant agent, prevents neurological deficits and cerebral injury following stroke per functional analysis, magnetic resonance imaging and histological assessment,” Current Neurovascular Research, vol. 9, no. 3, pp. 167–175, 2012. View at Publisher · View at Google Scholar
  39. F. C. Barone, W. J. Price, R. F. White, R. N. Willette, and G. Z. Feuerstein, “Genetic hypertension and increased susceptibility to cerebral ischemia,” Neuroscience and Biobehavioral Reviews, vol. 16, no. 2, pp. 219–233, 1992. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Y. Cui, Y. C. Zhu, S. Gao et al., “Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: a randomized, double-blind trial,” Chinese Medical Journal, vol. 126, no. 18, pp. 3405–3410, 2013. View at Google Scholar
  41. L. Zhang, L. Lu, W. M. Chan, Y. Huang, M. S. M. Wai, and D. T. Yew, “Effects of DL-3-n-butylphthalide on vascular dementia and angiogenesis,” Neurochemical Research, vol. 37, no. 5, pp. 911–919, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. X.-L. Lu, D. Luo, X.-L. Yao et al., “Dl-3n-butylphthalide promotes angiogenesis via the extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase/akt-endothelial nitric oxide synthase signaling pathways,” Journal of Cardiovascular Pharmacology, vol. 59, no. 4, pp. 352–362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Xu, Y. Wang, N. Li, L. Xu, H. Yang, and Z. Yang, “L-3-n-butylphthalide improves cognitive deficits in rats with chronic cerebral ischemia,” Neuropharmacology, vol. 62, no. 7, pp. 2423–2429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. H. M. Wang, T. Zhang, J. K. Huang, and X. J. Sun, “3-N-butylphathalide (NBP) attenuates the amyloid-β-induced inflammatory responses in cultured astrocytes via the nuclear factor-kB signaling pathway,” Cellular Physiology and Biochemistry, vol. 32, no. 1, pp. 235–242, 2013. View at Publisher · View at Google Scholar
  45. X. Feng, Y. Peng, M. Liu, and L. Cui, “Dl-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis,” Neuropharmacology, vol. 62, no. 2, pp. 1004–1010, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Peng, Y. Hu, S. Xu et al., “L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AβPP/PS1-Alzheimer's transgenic mice,” Journal of Alzheimer's Disease, vol. 29, no. 2, pp. 379–391, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Peng, J. Sun, S. Hon et al., “L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-β in a transgenic model of Alzheimer's disease,” Journal of Neuroscience, vol. 30, no. 24, pp. 8180–8189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. W. Wei, W. Zhang, Y. Huang et al., “The therapeutic effect of (DL)-3-n-butylphthalide in rats with chronic cerebral hypoperfusion through downregulation of amyloid precursor protein and matrix metalloproteinase-2,” Journal of International Medical, vol. 40, no. 3, pp. 967–975, 2012. View at Publisher · View at Google Scholar
  49. X. H. Feng, W. Yuan, Y. Peng, M. S. Liu, and L. Y. Cui, “Therapeutic effects of dl-3-n-butylphthalide in a transgenic mouse model of amyotrophic lateral sclerosis,” Chinese Medical Journal, vol. 125, no. 10, pp. 1760–1766, 2012. View at Google Scholar
  50. Q. Zhao, C. Zhang, X. Wang, L. Chen, H. Ji, and Y. Zhang, “(S)-ZJM-289, a nitric oxide-releasing derivative of 3-n-butylphthalide, protects against ischemic neuronal injury by attenuating mitochondrial dysfunction and associated cell death,” Neurochemistry International, vol. 60, no. 2, pp. 134–144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. M. H. Moghadam, M. Imenshahidi, and S. A. Mohajeri, “Antihypertensive efect of celery seed on rat blood pressure in chronic administration,” Journal of Medicinal Food, vol. 16, no. 6, pp. 558–563, 2013. View at Publisher · View at Google Scholar
  52. X. Wang, L. Wang, Z. Huang et al., “Synthesis and biological evaluation of nitric oxide releasing derivatives of 6-amino-3-n-butylphthalide as potential antiplatelet agents,” Bioorganic & Medicinal Chemistry Letters, vol. 23, no. 7, pp. 1985–1988, 2013. View at Publisher · View at Google Scholar
  53. I. P. Singh and S. Mahajan, “Berberine and its derivatives: a patent review (2009–2012),” Expert Opinion on Therapeutic Patents, vol. 23, no. 2, pp. 215–231.
  54. M. Ye, S. Fu, R. Pi, and F. He, “Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research,” Journal of Pharmacy and Pharmacology, vol. 61, no. 7, pp. 831–837, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. A. M. Han, H. Heo, and Y. K. Kwon, “Berberine promotes axonal regeneration in injured nerves of the peripheral nervous system,” Journal of Medicinal Food, vol. 15, no. 4, pp. 413–417, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Shigeta, K. Ootaki, H. Tatemoto, T. Nakanishi, A. Inada, and N. Muto, “Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by a coptidis rhizoma extract and protoberberine alkaloids,” Bioscience, Biotechnology and Biochemistry, vol. 66, no. 11, pp. 2491–2494, 2002. View at Google Scholar · View at Scopus
  57. Y. S. Chai, Z. Y. Yuan, F. Lei et al., “Inhibition of retinoblastoma mRNA degradation through poly-A-involved in the neuroprotective effect of berberine against cerebral ischemia,” PLoS ONE, vol. 9, no. 3, Article ID e90850, 2014. View at Google Scholar
  58. T. Lee, H. Heo, and Y. Kim Kwon, “Effect of berberine on cell survival in the developing rat brain damaged by MK-801,” Experimental Neurobiology, vol. 19, no. 3, pp. 140–145, 2010. View at Publisher · View at Google Scholar
  59. J.-H. Chen, S.-M. Huang, T.-W. Tan et al., “Berberine induces heme oxygenase-1 up-regulation through phosphatidylinositol 3-kinase/AKT and NF-E2-related factor-2 signaling pathway in astrocytes,” International Immunopharmacology, vol. 12, no. 1, pp. 94–100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Luo, H. Zhang, W.-W. Zhang et al., “Neuroprotective effect of Jatrorrhizine on hydrogen peroxide-induced cell injury and its potential mechanisms in PC12 cells,” Neuroscience Letters, vol. 498, no. 3, pp. 227–231, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. Y.-Q. Liu, M.-C. Cheng, L.-X. Wang, and H.-B. Xiao, “Rhizoma coptidis and berberine-induced activation of murine microglia N9 cells,” Journal of Ethnopharmacology, vol. 129, no. 1, pp. 121–126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. D.-Y. Lu, C.-H. Tang, Y.-H. Chen, and I.-H. Wei, “Berberine suppresses neuroinflammatory responses through AMP-activated protein kinase activation in BV-2 microglia,” Journal of Cellular Biochemistry, vol. 110, no. 3, pp. 697–705, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. F. Zhu and C. Qian, “Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1 beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease,” BMC Neuroscience, vol. 7, article 78, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. H. Li, X. L. Li, M. Zhang et al., “Berberine ameliorates experimental autoimmune neuritis by suppressing both cellular and humoral immunity,” Scandinavian Journal of Immunology, vol. 79, no. 1, pp. 12–19, 2014. View at Publisher · View at Google Scholar
  65. D. P. Singh and K. Chopra, “Verapamil augments the neuroprotectant action of berberine in rat model of transient global cerebral ischemia,” European Journal of Pharmacology, vol. 720, no. 1–3, pp. 98–106, 2013. View at Publisher · View at Google Scholar
  66. P. Bhutada, Y. Mundhada, K. Bansod et al., “Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes,” Behavioural Brain Research, vol. 220, no. 1, pp. 30–41, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Kim, K. H. Cho, M. S. Shin et al., “Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease,” International Journal of Molecular Medicine, vol. 33, no. 4, pp. 870–878, 2014. View at Google Scholar
  68. M. Asai, N. Iwata, A. Yoshikawa et al., “Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Aβ secretion,” Biochemical and Biophysical Research Communications, vol. 352, no. 2, pp. 498–502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. S. K. Kulkarni and A. Dhir, “Possible involvement of l-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride,” European Journal of Pharmacology, vol. 569, no. 1-2, pp. 77–83, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. S. K. Kulkarni and A. Dhir, “On the mechanism of antidepressant-like action of berberine chloride,” European Journal of Pharmacology, vol. 589, no. 1–3, pp. 163–172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. W.-H. Peng, K.-L. Lo, Y.-H. Lee, T.-H. Hung, and Y.-C. Lin, “Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice,” Life Sciences, vol. 81, no. 11, pp. 933–938, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Chu, G. Jin, E. Friedman, and X. Zhen, “Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addiction,” Cellular and Molecular Neurobiology, vol. 28, no. 4, pp. 491–499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. W.-H. Peng, C.-R. Wu, C.-S. Chen, C.-F. Chen, Z.-C. Leu, and M.-T. Hsieh, “Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors,” Life Sciences, vol. 75, no. 20, pp. 2451–2462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Maes, “Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs,” Psychiatry Research, vol. 58, no. 3, pp. 217–225, 1995. View at Publisher · View at Google Scholar · View at Scopus
  75. H. K. Moghaddam, T. Baluchneijadmojarad, M. Roghani et al., “Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats,” Molecular Neurobiology, vol. 49, no. 2, pp. 820–826, 2014. View at Publisher · View at Google Scholar
  76. F. di Pierro, P. Putignano, N. Villanova et al., “Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum mariaum standardized extracts versus only Berberis aristata in patients with type 2 diabetes,” Clinical Pharmacology, vol. 19, no. 5, pp. 167–174, 2013. View at Google Scholar
  77. L. Zhang, W. P. Lam, L. Lu et al., “How would composite traditional Chinese medicine protect the brain—an example of the composite formula “Pien Tze Huang”,” Current Medicinal Chemistry, vol. 18, no. 23, pp. 3590–3594, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Wang, D. Zheng, J. Xu, W. Lam, and D. T. Yew, “Brain damages in ketamine addicts as revealed by magnetic resonance imaging,” Frontiers in Neuroanatomy, vol. 7, article 23, 2013. View at Google Scholar
  79. L. Sun, Q. Li, Y. Zhang et al., “Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys,” Addiction Biology, vol. 19, no. 2, pp. 185–194, 2012. View at Publisher · View at Google Scholar
  80. L. Zhang, W. P. Lam, L. Lu et al., “Protective effects and potential mechanisms of Pien Tze Huang on cerebral chronic ischemia and hypertensive stroke,” Chinese Medicine, vol. 5, article 35, 2010. View at Publisher · View at Google Scholar · View at Scopus